SCHEMBL8382155

SCHEMBL8382155

O=C(Nc1ccc2[nH]cc(C3=CCN4CCCC4C3)c2c1)c1ccco1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.45
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
KDM4E B2RXH2 4/20 0.45
HPGD P15428 4/20 0.45
CASP1 P29466 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
RAB9A P51151 8/20 0.43
NPC1 O15118 7/20 0.43
TP53 P04637 3/20 0.43
LMNA P02545 2/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
NOS3 P29474 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8383851 0.97 MAPT (0.45) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL8386551 0.86 NOS3 (0.54) MAPTLMNANOS3NOS1
Hydrochloric Acid SCHEMBL8386484 0.85 NOS3 (0.56) MAPTLMNANOS3NOS1
SCHEMBL8386416 0.85 NOS3 (0.42) RAB9ANOS3NOS1
SCHEMBL30908982 0.84 NPC1 (0.45) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL8386469 0.84 NPC1 (0.45) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL8387372 0.83 NOS3 (0.44) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL8382972 0.83 HTR1D (0.54) RAB9ANPC1NOS3NOS1
SCHEMBL30908829 0.82 NOS3 (0.45) MAPTALDH1A1KDM4EHPGDMEN1
SCHEMBL8382948 0.82 NOS3 (0.45) MAPTALDH1A1KDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
US-5874427-A MIGRAINE ELI LILLY AND COMPANY (US) 1999-02-23 US disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed
WO-1998046570-A1 SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 1998-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D MAPT 3544/4885ALDH1A1 563/4885SMN1; SMN2 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.